Institutional Review Board, Hospital for Special Surgery
November 29, 2016
The safety of study participants is our top priority. The trial is approved and periodically reviewed by an Institutional Review Board (IRB), which includes doctors, administrators, ethicists, and members of the general public. The safety of clinical trials is reviewed by the U.S. Food and Drug Administration.
Before enrolling in a clinical trial, the investigator will explain the purpose of the trial, its expected benefits, any possible risks or side effects, and what your role will be. This is the time to ask questions! If you want to join the trial, you must sign the informed consent documents. You can leave a clinical trial at any time without penalty.
For further information, see Understanding Clinical Trials.
This research is being done to help doctors find the best way to ask people living with rheumatoid arthritis (RA) about their health. We will use this research to develop a questionnaireto use in rheumatology clinics that collects information from patients about symptoms that people living with RA think are most important. This questionnaire may be used to help doctors and people living with RA make decisions about how best to treat their RA. This study is seeking approximately 75 patients to enroll for a total of 3 visits each. The visits will occur at any 3 concurrent visits to your HSS rheumatologist. We expect that participants will be able to complete the questionnaire in 1030
minutes as a waiting room activity.
A person who is 18 years or older, is able to read and speak english, and has been diagnosed with Rheumatoid Arthritis may enroll. A patient is ineligible if s/he has been diagnosed with an inflammatory disease other than Rheumatoid Arthritis, has a diagnosis or history of psoriasis or psoriatic arthritis, and/or has a family history
of psoriasis or psoriatic arthritis.
Manager, Inflammatory Arthritis Center